for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cortexyme Inc

CRTX.OQ

Latest Trade

57.30USD

Change

1.70(+3.06%)

Volume

350,809

Today's Range

55.95

 - 

57.54

52 Week Range

20.49

 - 

73.28

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
55.60
Open
56.45
Volume
350,809
3M AVG Volume
2.23
Today's High
57.54
Today's Low
55.95
52 Week High
73.28
52 Week Low
20.49
Shares Out (MIL)
29.49
Market Cap (MIL)
1,689.64
Forward P/E
-23.43
Dividend (Yield %)
--

Latest Developments

More

Cortexyme Announces Q2 2020 Financial Results And Provides Business Update

Cortexyme Announces Q1 Loss Per Share Of $0.61

Cortexyme Reports Q4 Loss Per Share Of $0.46

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cortexyme Inc

Cortexyme, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The Company is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.

Industry

Biotechnology & Drugs

Contact Info

269 E Grand Ave

SOUTH SAN FRANCISCO, CA

94080-4804

United States

+1.415.9105717

https://www.cortexyme.com/

Executive Leadership

Casey C. Lynch

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Stephen S. Dominy

Co-Founder, Chief Scientific Officer, Director

Christopher P. Lowe

Chief Financial Officer, Treasurer

Leslie Holsinger

Executive Vice President - Preclinical Development

Caryn McDowell

Chief Legal and Administrative Officer, Corporate Secretary

Key Stats

2.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-1.943

2020(E)

-2.445
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
8.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-33.37
Return on Equity (TTM)
-31.47

Latest News

Latest News

BRIEF-Cortexyme Announces Q1 Loss Per Share Of $0.61

* CORTEXYME ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Cortexyme Publishes Data On P. Gingivalis Ability To Infect Neurons, Drive Alzheimer’S-Like Pathology In The Journal Of Alzheimer’S Disease

* CORTEXYME PUBLISHES DATA ON P. GINGIVALIS ABILITY TO INFECT NEURONS, DRIVE ALZHEIMER’S-LIKE PATHOLOGY IN THE JOURNAL OF ALZHEIMER’S DISEASE Source text for Eikon: Further company coverage:

BRIEF-Cortexyme Files For Secondary Stock Offering of Up To 2.5 Mln Shares

* FILES PROSPECTUS RELATES TO RESALE, FROM TIME TO TIME, OF UP TO 2.5 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS Source text: (https://bit.ly/2JPM6Ou) Further company coverage:

BRIEF-Cortexyme Reports Q4 Loss Per Share Of $0.46

* CORTEXYME ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Cortexyme Announces Gain Trial In Alzheimer's Disease Has Reached Enrollment Milestone Of 300 Patients

* CORTEXYME ANNOUNCES GAIN TRIAL IN ALZHEIMER’S DISEASE HAS REACHED ENROLLMENT MILESTONE OF 300 PATIENTS

BRIEF-Cortexyme Provides Regulatory Update For COR388 Development Program In Alzheimer’S Disease

* CORTEXYME PROVIDES REGULATORY UPDATE FOR COR388 DEVELOPMENT PROGRAM IN ALZHEIMER’S DISEASE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up